Nirav Dhanesha Lab - LSU Health Shreveport

Nirav Dhanesha, PhD

Assistant Professor
Graduate Program Director
Department of Pathology and Translational Pathobiology

Education / Training
B.Pharm (2001-2005) – North Gujarat University, India
M.Pharm (2005-2007) –Gujarat University, India.
PhD (2010-2014) – KSV University and Zydus Research Center, India
Post‐Doctoral Fellow (2014-2019)– University of Iowa

News

2025

Harpreet received Third Prize in 2025 BRAID Conference poster presentation.
Nirvana was selected for an oral talk entitled “The Receptor Tyrosine Kinase EphA2 Promotes Thrombogenesis and Impairs Thrombus Resolution in DVT” at the 67th ASH Annual Meeting and Exposition, Orlando, FL.
Dr Dhanesha was selected for an oral talk entitled “Discovery and Preclinical Characterization of SB-01, a Novel Allosteric Inhibitor of Human Factor XIa” at the 67th ASH Annual Meeting and Exposition, Orlando, FL.
Harpreet was selected for an Oral Presentation at International Stroke Conference, for her talk about “Modulation of Neutrophil Integrin α9 Enhances Microglial Efferocytosis and Neurological Recovery in a mice model of Subarachnoid Hemorrhage”.
Harpreet presented poster at International Stroke Conference, 2025 on “Prolyl Hydroxylase Inhibitor Desidustat Improves Stroke Outcomes by Enhancing Microglial Efferocytosis in Mice with Chronic Kidney Disease”.
Dr Dhanesha was invited to deliver an oral talk at the Department of Pharmacology, Tulane School of Medicine, New Orleans.
Our study titled " Prolyl hydroxylase inhibitor desidustat improves stroke outcomes via enhancing efferocytosis in mice with chronic kidney disease" was published in the Experimental Neurology.
Evan was awarded with T32 fellowship.
Our study titled " Neutrophil Integrin α9 Impairs Efferocytosis and Worsens Long-Term Recovery After Subarachnoid Hemorrhage" was published in the ATVB.
Harpreet was selected for a poster presentation at Society for Neuroscience, 2025.
Harpreet won second prize in poster presentation in National postdoc Appreciation week.
Nilesh received American Heart Association (AHA) Postdoctoral Fellowship Award.
Nilesh won first Prize in poster presentation, Malcolm Feist Cardiovascular research symposium, 2025.
Nilesh won Early Career Award at ISTH 2025 Congress, Washington, D.C.
Nilesh was selected for oral presentation entitled “Neutrophil CD14 Promotes Deep Vein Thrombus Formation via Procoagulant Platelet Formation” at ISTH 2025 Congress, Washington, D.C.
Dr Dhanesha was selected for oral presentation entitled “Hepatic Oxalate Overproduction Exacerbates DVT in Metabolic Dysfunction-Associated Steatohepatitis” at ISTH 2025 Congress, Washington, D.C.

2024

Dr Dhanesha was invited to deliver an oral talk at the Vascular Discovery: From Genes to Medicine Scientific Sessions in Chicago.
Our study titled "Interactions between integrin α9β1 and VCAM-1 promote neutrophil hyperactivation and mediate poststroke DVT" was published in the Blood Advances.
Dr Dhanesha was invited to deliver an oral talk at the Center for Translational Research on Inflammatory Diseases (CTRID), Baylor College of Medicine.
Harpreet was selected for an oral Presentation at International Stroke Conference, at Phoenix to talk about Integrin α9β1 and VCAM-1 Interaction Promotes Neutrophil Hyperactivation and Cognitive Decline following Subarachnoid Hemorrhage.
Harpreet received AHA post-doctoral fellow Award 2024.
Harpreet received First Prize in BRAID Conference poster presentation.
Nilesh received Center for Cardiovascular Diseases and Sciences (CCDS) Malcolm Feist Cardiovascular Research Postdoctoral Fellowship (Intramural)
Nilesh received ASH Abstract Achievement Award, The American Society of Hematology at 66th ASH Annual Meeting and Exposition, San Diego, CA.
Nilesh was selected for an oral talk entitled “Targeting Neutrophil CD14 Inhibits Deep Vein Thrombus Formation and Enhances Thrombus Resolution Following Inferior Vena Cava Stenosis in Mice” at the 66th ASH Annual Meeting and Exposition, San Diego, CA.
Our study titled "Enhanced venous thrombosis and hypercoagulability in murine and human metabolic dysfunction-associated steatohepatitis" was published in the Journal of Thrombosis and Haemostasis.

2023

Harpreet received CCDS Malcolm Feist Postdoctoral Fellowship.
Harpreet received Third Prize in Malcolm Feist CCDS poster presentation.
Harpreet received First Prize in BRAID Conference poster presentation.
Harpreet Kaur was awarded with Junior Investigator Awards ISC.
Nilesh received ASH Abstract Achievement Award, The American Society of Hematology at 65th ASH Annual Meeting and Exposition, San Diego, CA.
Nilesh was selected for an oral presentation entitled “Interactions between Integrin α9β1 and VCAM-1 Promote Neutrophil Hyperactivation and Deep Vein Thrombosis in a Murine Model of Lung Cancer” at the 65th ASH Annual Meeting and Exposition, San Diego, California.

Research

The Dhanesha Laboratory employs a robust, multidisciplinary approach to address critical questions in cerebrovascular diseases and thrombosis. We strategically combine data from human samples, sophisticated in vitro assays, and relevant preclinical models of both ischemic stroke and venous thrombosis to ensure translational impact.

Our current research portfolio is focused on four mechanistic and translational pillars:

Venous Thrombosis Pathogenesis: Defining novel mechanisms driving venous thrombosis, particularly in complex conditions such as lung cancer and metabolic dysfunction-associated steatohepatitis (MASH).
Stroke and Liver Crosstalk: Elucidating the bi-directional signaling between the brain and liver to identify and validate therapeutic targets that optimize stroke recovery and outcomes.
DVT Resolution: Developing cutting-edge strategies to improve the efficiency and quality of thrombus resolution following deep vein thrombosis (DVT).
Cellular Mechanisms: Investigating the essential mechanistic role of neutrophil integrin α9β1 in the pathogenesis of venous thrombosis under conditions of stroke and obesity.

These research endeavors has consistently generated high-impact results, accelerating the identification of new therapeutic targets for to improves outcomes in stroke and thrombosis. This work has successfully translated into extramural funding, patent applications, and 54 publications—including 17 as first author and 6 as corresponding author—in leading journals in thrombosis and vascular biology (Blood, Circulation, Circ Res, Stroke, JCI, ATVB, Sci Transl Med). This work has been recognized globally through invited talks, presentations at international scientific meetings, and a record of highly competitive awards.

Publications

Selected from 54 publications, 17 as first author, 6 as corresponding author.
Complete List of Published Work in My Bibliography

#Corresponding/senior author

Kaur H, Pandey N, Chandaluri L, Shaaban N, Kumar D, Pandit R, Martinez A, Anand SK, Das S, Rohilla S, Arias F, Reece E, Gaddam RR, Murnane KS, Vikram A, Mohandas R, Zhang X, Bhuiyan MAN, Lu XH, Orr AW, Rom O, Yurdagul A Jr, Dhanesha N^#. Neutrophil Integrin α9 Impairs Efferocytosis and Worsens Long-Term Recovery After Subarachnoid Hemorrhage. Arterioscler Thromb Vasc Biol. 2025 Jul 31:10.1161/ATVBAHA.125.323072. PMID: 40740133.
Pandey N, Kaur H, Chorawala MR, Anand SK, Chandaluri L, Butler ME, Aishwarya R, Gaddam SJ, Shen X, Alfaidi M, Wang J, Zhang X, Beedupalli K, Bhuiyan MS, Bhuiyan MAN, Buchhanolla P, Rai P, Shah R, Chokhawala H, Jordan JD, Magdy T, Orr AW, Stokes KY, Rom O, Dhanesha N^#. Interactions between integrin α9β1 and VCAM-1 promote neutrophil hyperactivation and mediate poststroke DVT. Blood Adv. 2024 May 14;8(9):2104-2117. PMID: 38498701. Featured as the Cover story in Blood Advances, volume 8, issue 9.
Kaur H, Pandey N, Chandaluri L, Shaaban N, Martinez A, Kidder E, Patel VJ, Kshirsagar SG, Kumar D, Frausto L, Pandit R, Richard KSE, Anand SK, Das S, Vikram A, Magdy T, Lu XH, Orr AW, Patel H, Trivedi RK, Kansagra K, Joharapurkar AA, Parmar DV, Jain MR, Rom O, Yurdagul A Jr, Dhanesha N^#. Prolyl hydroxylase inhibitor desidustat improves stroke outcomes via enhancing efferocytosis in mice with chronic kidney disease. Exp Neurol. 2025 Apr;386:115181. PMID: 39914641.
Pandey N, Anand SK, Kaur H, Richard KSE, Chandaluri L, Butler ME, Zhang X, Pearson-Gallion B, Rohilla S, Das S, Magdy T, Sethu P, Núñez KG, Orr AW, Stokes KY, Thevenot PT, Cohen AJ, Rom O, Dhanesha N#. Enhanced venous thrombosis and hypercoagulability in murine and human metabolic dysfunction-associated steatohepatitis. J Thromb Haemost. 2024 Dec;22(12):3572-3580. PMID: 39306095.
Dhanesha N^#, Jain M, Doddapattar P, Undas A, Chauhan AK. Cellular fibronectin promotes deep vein thrombosis in diet-induced obese mice. J Thromb Haemost. 2021 Mar;19(3):814-821. PMID: 33300307
Dhanesha N, Nayak MK, Doddapattar P, Jain M, Flora GD, Kon S, Chauhan AK. Targeting myeloid-cell specific integrin α9β1 inhibits arterial thrombosis in mice. Blood. 2020 Mar 12;135(11):857-861. PMID: 31951649.
Dhanesha N, Jain M, Tripathi AK, Doddapattar P, Chorawala M, Bathla G, Nayak MK, Ghatge M, Lentz SR, Kon S, Chauhan AK. Targeting Myeloid-Specific Integrin α9β1 Improves Short- and Long-Term Stroke Outcomes in Murine Models With Preexisting Comorbidities by Limiting Thrombosis and Inflammation. Circ Res. 2020 Jun 5;126(12):1779-1794. PMID: 32195632.
Dhanesha N, Ahmad A, Prakash P, Doddapattar P, Lentz SR, Chauhan AK. Genetic Ablation of Extra Domain A of Fibronectin in Hypercholesterolemic Mice Improves Stroke Outcome by Reducing Thrombo-Inflammation. Circulation. 2015 Dec 8;132(23):2237-47. PMID: 26508731 Editorial in Circulation. Messina LM. Toward a Biological Therapy to Improve Stroke Outcomes After Thrombolytic Therapy. Circulation. 2015 Dec 8;132(23):2201-2
Dhanesha N, Chorawala MR, Jain M, Bhalla A, Thedens D, Nayak M, Doddapattar P, Chauhan AK. Fn-EDA (Fibronectin Containing Extra Domain A) in Plasma, but Not Endothelial Cells, Exacerbates Stroke Outcome by Promoting Thrombo-Inflammation. Stroke. 2019 May;50(5):1201-1209. PMID: 30909835
Dhanesha N, Prakash P, Doddapattar P, Khanna I, Pollpeter MJ, Nayak MK, Staber JM, Chauhan AK. Endothelial Cell-Derived von Willebrand Factor Is the Major Determinant That Mediates von Willebrand Factor-Dependent Acute Ischemic Stroke by Promoting Postischemic Thrombo-Inflammation. Arterioscler Thromb Vasc Biol. 2016;36(9):1829‐1837. PMID: 27444201
Dhanesha N, Schnell T, Rahmatalla S, DeShaw J, Thedens D, Parker BM, Zimmerman MB, Pieper AA, Chauhan AK, Leira EC. Low-Frequency Vibrations Enhance Thrombolytic Therapy and Improve Stroke Outcomes. Stroke. 2020 Jun;51(6):1855-1861. PMID: 32397935.

Team

Nirav Dhanesha, PhD

Principal Investigator
nirav.dhanesha@lsuhs.edu

The Dhanesha Lab is dedicated to combating the life-threatening impact of venous thromboembolism (VTE) and Cerebrovascular disease. Our long-term pharmacological research is centered on a clear, vital vision: to fundamentally rewrite the treatment paradigm by fully elucidating the mechanistic core of thrombo-inflammation.We utilize a robust, multi-stage translational approach:
Discovery: Leveraging crucial human biological samples for the unbiased identification of novel therapeutic targets.
Validation: Rigorously testing and validating these targets using sophisticated in vivo and in vitro experimental models.
Translation: Identifying and developing safe, effective, and transformative therapeutic strategies that promise better long-term outcomes for patients affected by VTE and stroke.

Our mission is to translate molecular insights into clinical reality, improving patient survival and quality of life.